Coherus Has $2.2bn Revenue Ambition By 2026 – But Humira Is Key
Yusimry Adalimumab Biosimilar Uptake Is ‘Key Swing’ For Company Projections
During the company’s landmark first annual analyst day, Coherus BioSciences management spoke at length about its ambitions for Coherus to generate north of $2bn in revenues by 2026, with much riding on how it fares in the impending biosimilar Humira market.
You may also be interested in...
Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.
Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.
Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.